Monograph Capital
-
Autoimmune Drug Biotech HI-Bio Unveils $120M to Root Out Cellular Drivers of Disease
Human Immunology Biosciences aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.